All In MedTech

FDA Clearance Tracker · P160002-S002

Ventana PD-L1 (SP142) Assay

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 6, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 6, 2017

Approved

Time to decision

82 days

Received Mar 16, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P160002-S002
Device name
Ventana PD-L1 (SP142) Assay
Applicant location
Tucson, AZ
Received
Mar 16, 2017
Decided
Jun 6, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160002

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approval for updated product labeling with additional non-clinical data.

Source documents

Other decisions for Ventana Medical Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.